ClinVar Miner

Submissions for variant NM_002834.5(PTPN11):c.226G>C (p.Glu76Gln)

dbSNP: rs121918464
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000159045 SCV000208987 pathogenic not provided 2014-08-04 criteria provided, single submitter clinical testing he E76Q missense mutation has not be reported as a benign polymorphism or as a disease-causing mutation, to our knowledge. The E76Q missense change is a non-conservative amino acid substitution with a negatively charged residue (Glu) being replaced by a neutral residue (Gln). It lies in the N-SH2 domain of the gene, which is a hot spot for Noonan syndrome mutations. Several other missense mutations at this codon (E76A, E76K and E76V) have been reported as somatic mutations in association with juvenile myelomonocytic leukemia (JMML) and other hematologic malignancies (Mori et al., 2004 and Tartaglia et al., 2006). However, another missense mutation at this codon (E76D) has been reported previously as a germline mutation in association with Noonan syndrome (Tartaglia et al., 2001 and Tartaglia et al., 2006). The variant is found in NOONAN panel(s).
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV001813410 SCV002060930 pathogenic Noonan syndrome and Noonan-related syndrome 2017-05-15 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002281971 SCV002570731 pathogenic RASopathy 2022-07-25 criteria provided, single submitter clinical testing Variant summary: PTPN11 c.226G>C (p.Glu76Gln) results in a conservative amino acid change located in the SH2 domain (IPR000980) of the encoded protein sequence. Other variants at the same codon, p.Glu76Ala, p.Glu76Asp, p.Glu76Gly and p.Glu76Val have been reported in association with Noonan syndrome supporting a mutational hotspot and a critical residue required for protein function. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251068 control chromosomes. c.226G>C has been reported in the literature as a de-novo germline variant in at-least one fetus prenatally affected with Noonan Syndrome (example, Malniece_2020). At least one publication reports experimental evidence evaluating an impact on protein function, demonstrating that the variant resulted in increased phosphatase activity as compared with wild type, therefore, this alteration is predicted to be activating (LaRochelle_2016). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
MGZ Medical Genetics Center RCV002288669 SCV002581080 pathogenic Noonan syndrome 1 2022-07-07 criteria provided, single submitter clinical testing
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center RCV002288669 SCV004806648 likely pathogenic Noonan syndrome 1 2024-03-26 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.